Drug Profile
ASP 2409
Alternative Names: ASP2409Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Perseid Therapeutics
- Developer Astellas Pharma
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 30 Apr 2014 Astellas Pharma completes a phase I trial in Rheumatoid arthritis in USA (NCT02171143)
- 01 Nov 2013 Discontinued - Phase-I for Transplant rejection in Japan (Parenteral)
- 01 Feb 2012 Phase-I clinical trials in Transplant rejection in Japan (Parenteral)